[8-K] Silo Pharma, Inc. Reports Material Event

Rhea-AI Filing Summary

CH Robinson Worldwide (CHRW) – Form 4 insider filing

On 01 Jul 2025, director Mark A. Goodburn received 380 immediately-vested Phantom Stock/RSUs at a reference price of $95.95 per share under the company’s director compensation deferral program. After the grant, Goodburn now holds 2,280 common shares directly plus 12,038 RSUs that convert 1-for-1 into common stock upon his departure from the board. No shares were sold and no cash changed hands; the transaction simply converts a quarterly cash retainer into equity, modestly increasing the director’s alignment with shareholders. The filing does not disclose any broader operational or financial information and is routine in nature.

Insights

Financial Analyst

TL;DR: Routine RSU grant; neutral impact on CHRW valuation.

The filing records a small equity award (≈US$36k) to director Mark Goodburn for deferring his cash retainer. Beneficial ownership rises to 12,038 RSUs plus 2,280 shares, a negligible fraction of CHRW’s ~118 million shares outstanding. No purchases or sales of common stock occurred, so market supply–demand dynamics are unaffected. While insider equity retention is directionally positive for governance, the size is immaterial; therefore the disclosure is considered neutral for investors.

false 0001514183 0001514183 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2025

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On June 27, 2025, Silo Pharma, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock from May 14, 2025 to June 26, 2025, the Company no longer meets this requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol “Silo.”

The Notification Letter provides that the Company has 180 calendar days, or until December 24, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by December 24, 2025, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: July 3, 2025	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

2

FAQ

What did CHRW director Mark Goodburn acquire on 1 July 2025?

He received 380 phantom stock/restricted stock units that settle in common shares after he leaves the board.

How many C.H. Robinson (CHRW) shares does Goodburn own after the transaction?

He beneficially owns 2,280 common shares directly and 12,038 RSUs.

Was any CHRW stock sold in this Form 4 filing?

No. The filing reports only an equity grant; there were no sales or disposals of shares.

Why were the RSUs issued at a price of $95.95?

The price reflects the reference market price used to convert the director’s deferred cash retainer into equity units.

Do the newly granted RSUs vest over time?

They are immediately vested; payout in shares occurs according to a schedule chosen by Goodburn after his board service ends.